LEETRO
430425
Geovis Insighter Technology
920116
Beijing Global Safety Technology
300523
Zhejiang JW Precision Machinery
300984
Wintao Communications
301139
CN Stock MarketDetailed Quotes
002750 Kunming Longjin Pharmaceutical
- 1.46
- +0.03+2.10%
Not Open Mar 5 15:00 CST
584.73MMarket Cap-10.90P/E (TTM)
1.50High1.36Low189.70KlotVolume1.36Open1.43Pre Close27.30MTurnover4.76%Turnover RatioLossP/E (Static)400.50MShares9.0552wk High1.16P/B582.15MFloat Cap1.3352wk Low1.50Limit Up398.74MShs Float26.32Historical High1.36Limit Down9.79%Amplitude1.33Historical Low--Dividend TTM1.44Avg Price82.90KlotAsk--Div YieldTTM100Lot Size74.57KlotBid
Kunming Longjin Pharmaceutical News
Express News | *ST Longjin: The supplement application approval notice for Febuxostat Tablets has been obtained.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Express News | With stricter regulations and market reshuffling, two more Traditional Chinese Medicine injection companies are on the brink of being Delisted.
4 consecutive limit-ups Special Treat Longjin (002750.SZ): there is a risk of being delisted.
*Special Treat Longjin (002750.SZ) announced that the company has disclosed its performance forecast for the year 2024, expecting relevant...
*ST Longjin: The company's Stocks may be delisted.
On February 11, Gelonghui reported that *ST Longjin announced that the company's Stocks will be subject to a Delisting risk warning starting from the opening of the market on May 6, 2024. If the company's annual report for 2024 reveals circumstances specified in Article 9.3.12 of the Shenzhen Stock Exchange's Listing Rules, there is a risk of the company's Stocks being terminated from listing. The company has disclosed its 2024 annual performance forecast, expecting that relevant Indicators will meet the aforementioned conditions. If the audited financial data of the final disclosed 2024 annual report is consistent with the performance forecast data, the company's Stocks will be delisted from the Shenzhen Stock Exchange.
*ST Longjin: 2024 performance forecast
*Special Treat Longjin (002750.SZ): Expected loss of 29.8162 million yuan to 44.3776 million yuan for the year 2024.
*ST Longjin (002750.SZ) announced its performance forecast for 2024 on January 21, with a total profit loss expected between 33.2562 million yuan to 49.4976 million yuan. The net income attributable to shareholders of the listed company is expected to be a loss between 29.8162 million yuan to 44.3776 million yuan, while the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses is expected to be a loss between 38.0034 million yuan to 56.5632 million yuan. The basic EPS is expected to be a loss between 0.0744 yuan/share to 0.1108 yuan/share, with revenue between 50.865 million yuan to 74 million yuan.
*Special Treat Longjin (002750.SZ): The holding subsidiary has obtained the Pharmaceutical registration certificate.
On January 3, Glonghui reported that *ST Longjin (002750.SZ) announced that its holding subsidiary Yunnan Longjin Kangyou Biomedical Co., Ltd. recently received the drug registration certificate for Ezetimibe tablets issued by the National Medical Products Administration (Certificate No.: 2024S30289). Ezetimibe tablets are cholesterol absorption inhibitors, initially developed in collaboration with Merck and Schering-Plough, and were approved for import into China in 2006. The original research compound patent in China expired in 2022, and it is mainly used clinically to treat primary hypercholesterolemia and homozygous familial hypercholesterolemia.
Express News | Midday announcement: Longhua New Materials' wholly-owned subsidiary is conducting trial production for the Nylon 66 Phase I project.
*Special Treat Longjin (002750.SZ): Received the pharmaceutical registration certificate for sildenafil citrate orally disintegrating tablets.
ST Longjin (002750.SZ) released an announcement that the company's controlling subsidiary, Yunnan Longjin Kangyou Biomedical Co., Ltd...
*ST Longjin: 2024 Third Quarter Report
*ST Longjin: 2024 Semi-Annual Report Summary
*ST Longjin: 2024 Semi-Annual Report
ST Longjin (002750.SZ) released its performance for the first half of the year, with a net loss of 4.224 million yuan.
*ST Longjin (002750.SZ) released its 2024 semi-annual report, during the reporting period, the company achieved operating income...
Special treat Longjin (002750.SZ): As of August 9, the number of shareholders in the company was 38,065.
On August 14th, Gelunhui reported that as of the latest date of August 9, 2024, the number of shareholders in Special Treat Longjin (002750.SZ) was 38,065.
Express News | *ST Longjin: There are no major issues that should have been disclosed but have not been disclosed.
Kunming Longjin Pharmaceutical: 2024 Interim Performance Forecast
*Special Treat Longjin (002750.SZ): Expected to lose between 3.6 million yuan and 4.9 million yuan in the first half of the year.
On July 10th, Gelunhui reported that *ST Longjin (002750.SZ) announced its performance forecast for the first half of 2024, with a net loss of 3.6 million yuan to 4.9 million yuan attributable to shareholders of the listed company, compared with a loss of 15.7777 million yuan in the same period last year. After deducting non-recurring gains and losses, the net loss was 9.7 million yuan to 13.15 million yuan, compared with a loss of 19.4725 million yuan in the same period last year. The basic earnings per share were expected to be between a loss of 0.0090 yuan/share and a loss of 0.0122 yuan/share. Due to the continued impact of policy factors such as medical insurance payment restrictions, hospital prescription restrictions, and the company's injection of scutellaria baicalensis extract price reduction by 67%.
Longjin Pharmaceutical (002750.SZ): Net loss of 4.4918 million yuan in the first quarter
Gelonghui, April 29 | Longjin Pharmaceutical (002750.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 26.3884 million yuan, up 22.43% year on year; net profit attributable to shareholders of listed companies was 4.4918 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 6.1091 million yuan; basic earnings per share - 0.0112 yuan.
The traditional Chinese medicine sector fell at the beginning of the market, and Dali Pharmaceutical fell more than 8%
Gelonghui, March 28 | Dali Pharmaceutical fell more than 8%, followed by Longjin Pharmaceutical, Xiangxue Pharmaceutical, Kanghui Pharmaceutical, and Guangdong Wannianqing.
